Can we Reduce the Number of Vaccine Injections for Children?

PHASE4CompletedINTERVENTIONAL
Enrollment

404

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

July 31, 2013

Conditions
Invasive Meningococcal Disease
Interventions
BIOLOGICAL

Glyco-conjugate Neisseria meningitidis serogroup C (MenC) vaccine

"In order to ensure proper intramuscular injection of the study vaccines, a 23G (0.5mm in diameter) needle of at least 1 inch (2.54 cm) length will be used. All vaccines will be administered intramuscularly.~Then MenC vaccine will administered either once (at 3 months) or twice (at 3 and 4 months) depending on treatment group to either the thigh, deltoid or a combination of the two."

BIOLOGICAL

Routine schedule immunisations except monovalent MenC vaccine

Routine schedule immunisations will be given according to NHS guidelines.

Trial Locations (1)

Unknown

Oxford Vaccine Group, Oxford

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Oxford University Hospitals NHS Trust

OTHER

collaborator

GlaxoSmithKline

INDUSTRY

lead

University of Oxford

OTHER